Similarly, dysregulation in TP53 gene is one of the most frequent events that occurs in approximately 60% of CRC patients and TP53 mutational status is highly associated with CRC progression and poorer clinical outcome (Muzny et al., 2012; Robles, Jen and Harris, 2016; Nakayama and Oshima, 2019). This evidence concerns the gene TP53 and colorectal carcinoma.